The BioPharma industry is in rapid flux, shaped by rising tariffs, shifting policies, and new barriers to prescription access. Here’s a quick look at the forces driving change.
Pharma Companies Announce Direct-to-Consumer Sales and Price Cuts in US
Source: Reuters
Several major pharmaceutical companies are responding to recent U.S. policy shifts by cutting drug prices and announcing plans to sell medications directly to patients. With the government’s TrumpRx.gov platform set to launch in early 2026, the move could reshape how Americans access and pay for their prescriptions.
Consistency in the Chaos: FDA Approvals Within Average Range as Q4 Kicks Off
Source: BioSpace
Despite a turbulent year marked by leadership shakeups and policy uncertainty, the FDA’s pace of drug approvals in 2025 remains steady. Analysts suggest that, even amid upheaval and shifting priorities, the agency continues to advance new therapies—especially for rare diseases and oncology.
WHO Warns of Widespread Resistance to Common Antibiotics Worldwide
Source: World Health Organization
A new WHO report reveals a troubling rise in antibiotic resistance, with one in six common bacterial infections worldwide resistant to treatment in 2023. The findings highlight the urgent need for stronger global action to preserve the effectiveness of essential medicines.
